Gold(III)-dithiocarbamato peptidomimetics in the forefront of the targeted anticancer therapy: preclinical studies against human breast neoplasia.
Since the serendipitous discovery of cisplatin, platinum-based drugs have become well-established antitumor agents, despite the fact that their clinical use is limited by many severe side-effects. In order to both improve the chemotherapeutic index and broaden the therapeutic spectrum of current dru...
Main Authors: | Chiara Nardon, Sara M Schmitt, Huanjie Yang, Jian Zuo, Dolores Fregona, Q Ping Dou |
---|---|
Format: | Article |
Language: | English |
Published: |
Public Library of Science (PLoS)
2014-01-01
|
Series: | PLoS ONE |
Online Access: | http://europepmc.org/articles/PMC3879379?pdf=render |
Similar Items
-
Gold(III) to Ruthenium(III) Metal Exchange in Dithiocarbamato Complexes Tunes Their Biological Mode of Action for Cytotoxicity in Cancer Cells
by: Maria Dalla Pozza, et al.
Published: (2021-07-01) -
Pyroptosis at the forefront of anticancer immunity
by: Reid Loveless, et al.
Published: (2021-08-01) -
CD103+ cells at the forefront of anticancer immunity
by: Claire Vanpouille-Box, et al.
Published: (2017-11-01) -
Design, Synthesis and Screening of Peptidomimetics for Anticancer and Antiviral Drug Candidates
by: Liang, Yi
Published: (2016) -
Synthesis and characterization of tris[butyl-(1-methyl-3phenyl-propyl)-dithiocarbamato]cobalt(III) seskvitoluen
by: Kaluđerović Goran N., et al.
Published: (2002-01-01)